KR20080074182A - 연골 손상에 사용하기 위한 약제 - Google Patents

연골 손상에 사용하기 위한 약제 Download PDF

Info

Publication number
KR20080074182A
KR20080074182A KR1020087014596A KR20087014596A KR20080074182A KR 20080074182 A KR20080074182 A KR 20080074182A KR 1020087014596 A KR1020087014596 A KR 1020087014596A KR 20087014596 A KR20087014596 A KR 20087014596A KR 20080074182 A KR20080074182 A KR 20080074182A
Authority
KR
South Korea
Prior art keywords
akg
alpha
acid
placebo
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087014596A
Other languages
English (en)
Korean (ko)
Inventor
스테판 지. 피에르지노브스키
Original Assignee
엔트레스 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔트레스 에이비 filed Critical 엔트레스 에이비
Publication of KR20080074182A publication Critical patent/KR20080074182A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020087014596A 2005-11-15 2006-11-15 연골 손상에 사용하기 위한 약제 Ceased KR20080074182A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59717205P 2005-11-15 2005-11-15
US60/597,172 2005-11-15

Publications (1)

Publication Number Publication Date
KR20080074182A true KR20080074182A (ko) 2008-08-12

Family

ID=38048916

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087014596A Ceased KR20080074182A (ko) 2005-11-15 2006-11-15 연골 손상에 사용하기 위한 약제

Country Status (10)

Country Link
US (2) US20090312427A1 (https=)
EP (1) EP1951218A4 (https=)
JP (1) JP2009515953A (https=)
KR (1) KR20080074182A (https=)
CN (2) CN101309678B (https=)
AU (1) AU2006316059A1 (https=)
BR (1) BRPI0618599A2 (https=)
CA (1) CA2629683A1 (https=)
RU (1) RU2454999C2 (https=)
WO (1) WO2007058612A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101309678B (zh) * 2005-11-15 2011-04-20 安特瑞斯公司 用于与软骨损伤有关的应用的药物
PL226695B1 (pl) 2006-07-03 2017-08-31 Danuta Kruszewska Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori
EP2106791A1 (en) * 2008-03-31 2009-10-07 Biotempt B.V. Glutamine or glutamine-containing dipeptide in a specific dosage for the treatment of inflammation
KR101080271B1 (ko) * 2009-03-31 2011-11-08 주식회사 웰스킨 다이펩타이드를 유효성분으로 포함하는 자외선에 의한 홍반반응 억제용 화장품 조성물
WO2011126163A1 (ko) * 2010-04-08 2011-10-13 주식회사 웰스킨 다이펩타이드를 포함하는 피부 미백용 조성물
CN113018288A (zh) * 2019-12-25 2021-06-25 同济大学 α-酮戊二酸在制备药物中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687782A (en) * 1984-12-10 1987-08-18 Nutri-Fuels Systems, Inc. Nutritional composition for enhancing skeletal muscle adaptation to exercise training
SE9303691D0 (sv) * 1993-11-09 1993-11-09 Gramineer Ab New beverage
AU7984498A (en) * 1997-06-25 1999-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Serum-free cell growth medium
US6846501B2 (en) * 2000-04-12 2005-01-25 Mid-America Commercialization Corporation Traditional snacks having balanced nutritional profiles
DE10057290B4 (de) * 2000-11-17 2004-01-08 Fresenius Kabi Deutschland Gmbh Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten
SE0201713D0 (sv) * 2001-11-23 2002-06-06 Gramineer Internat Ab New methods and use III
RU2211037C1 (ru) * 2001-12-29 2003-08-27 Институт органической и физической химии им. А.Е.Арбузова Казанского научного центра РАН Препарат селективного действия и способ лечения остеоартрозов
AU2003294221A1 (en) * 2002-09-13 2004-04-19 Kenneth E. Miller Method of alleviating pain via inhibition of neurotransmitter synthesis
EP1745791B1 (en) * 2003-05-07 2013-06-26 Osteologix A/S Treating cartilage/bone conditions with water-soluble strontium salts
US20050176807A1 (en) * 2004-02-09 2005-08-11 Friesen Kim G. Composition and method for use in cartilage affecting conditions
JP2005312402A (ja) * 2004-04-30 2005-11-10 Kanazawa Univ Tlo Inc グルタミン酸伝達系を利用した骨・軟骨疾患治療薬の評価方法
PL368573A1 (en) * 2004-06-17 2005-12-27 Sgp & Sons Ab Pharmaceutical compound influencing growth and mineralization processes in the axial and the appendicular skeleton as well as bone diseases of mature years among humans and animals as well as application of the pharmaceutical compound in the process of growth and mineralization of axial and appendicular skeleton and bone diseases of mature years among humans and animals
PL371081A1 (pl) * 2004-11-08 2006-05-15 Sgp & Sons Ab Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt
CN101309678B (zh) * 2005-11-15 2011-04-20 安特瑞斯公司 用于与软骨损伤有关的应用的药物

Also Published As

Publication number Publication date
EP1951218A1 (en) 2008-08-06
HK1126128A1 (en) 2009-08-28
EP1951218A4 (en) 2010-11-10
WO2007058612A1 (en) 2007-05-24
BRPI0618599A2 (pt) 2011-09-06
CN101309678A (zh) 2008-11-19
CN101843609A (zh) 2010-09-29
AU2006316059A1 (en) 2007-05-24
RU2454999C2 (ru) 2012-07-10
CN101309678B (zh) 2011-04-20
RU2008123806A (ru) 2009-12-27
US20090312427A1 (en) 2009-12-17
US20110082086A1 (en) 2011-04-07
CA2629683A1 (en) 2007-05-24
JP2009515953A (ja) 2009-04-16

Similar Documents

Publication Publication Date Title
KR100679778B1 (ko) PTHrP 유사체를 사용하는 골절 치료법
US20110082086A1 (en) Medicament for use in connection with cartilage impairment
JP4447913B2 (ja) オステオポローシス治療のための組成物の製造のためのグルタミン酸塩、グルタミン酸塩誘導体又はグルタミン酸塩代謝物、グルタミン酸塩アナログ或いはそれらの混合物の使用
KR20100014572A (ko) 오스테오칼신 함유 추출물의 제조방법
US20210128640A1 (en) Hyaluronic acid production promoting agent
KR20070040371A (ko) 혈장 지질을 낮추기 위한 알파 케토글루타레이트 및 관련화합물의 용도
US20160310578A1 (en) Method of accelerating osteogenesis
JP5969763B2 (ja) ヒト変形性膝関節症の予防剤および／または治療剤および／または増悪抑制剤
MX2008006203A (en) Medicament for use in connection with cartilage impairment
HK1126128B (en) Medicament for use in connection with cartilage impairment
HK1145285A (en) Medicament for use in connection with cartilage impairment
JP6855042B2 (ja) 関節症の症状を予防、軽減又は治療するための食品組成物及び経口医薬組成物
JP4340042B2 (ja) 軟骨生成促進剤及び軟骨損傷由来疾病予防治療剤
CN111012900B (zh) 一种具有增加骨密度功能的组合物及其制备方法与应用
JP2023048160A (ja) 破骨細胞分化抑制、筋肉量増加、運動機能改善、及び／又は筋力増強用組成物
KR20220041147A (ko) 시메티콘 및 수크로스 에스테르를 포함하는 조성물 및 소포제로서의 이의 용도
Andersson et al. Pharmacological treatment of osteopenia induced by gastrectomy or ovariectomy in young female rats
US20240424066A1 (en) Chondroprotective Nutraceutical Composition and Method of Using Same
KR20200038411A (ko) IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학 조성물
JP3752344B2 (ja) 抗骨粗鬆症剤
CN119745043A (zh) 一种改善骨关节健康的组合物及其应用
JPWO2018003817A1 (ja) 骨形成不全症等の予防及び／又は治療剤
EP1374904A1 (en) Preparation containing polymethyl-siloxane for nails, cartilage, bone joint, muscle and tendon disorders
JPWO2010109736A1 (ja) 軟骨生成促進剤および軟骨損傷由来疾病の予防治療剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080616

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20111115

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130503

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130722

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130503

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I